Regeneron Pharmaceuticals Shares Sold by Sovran Advisors

Institutional investor reduces stake in biotech company

Apr. 5, 2026 at 9:50am

Got story updates? Submit your updates here. ›

Sovran Advisors LLC, a hedge fund, reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.6% during the fourth quarter, according to a recent SEC filing. The fund now owns 8,619 shares of the biopharmaceutical company's stock, valued at $6.4 million.

Why it matters

Regeneron is a leading biotech firm known for its innovative drug discovery technologies. Institutional investors closely monitor changes in ownership of the company's stock, as it can signal shifts in market sentiment or changes in the company's outlook.

The details

According to the filing, Sovran Advisors sold 2,519 shares of Regeneron during the fourth quarter. The fund now owns 8,619 shares, down from 11,138 shares at the end of the previous quarter. Other hedge funds and institutional investors have also modified their holdings of Regeneron in recent quarters.

  • The share sale occurred during the fourth quarter of 2025.
  • Sovran Advisors filed the disclosure with the SEC on April 5, 2026.

The players

Sovran Advisors LLC

A hedge fund that previously held a position in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Sovran Advisors' Regeneron holdings suggests a potential shift in market sentiment around the biotech company, though the reasons behind the sale are not entirely clear. Investors will likely continue to monitor changes in institutional ownership of Regeneron stock for insights into the company's performance and outlook.